期刊
PLOS ONE
卷 13, 期 9, 页码 -出版社
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0203659
关键词
-
资金
- National Institute on Aging (Arizona Alzheimer's Disease Core Center) [P30 AG19610]
- Arizona Department of Health Services (Arizona Alzheimer's Research Center) [211002]
- Arizona Biomedical Research Commission [ADHS14-082999, 4001, 0011, 05-901, 1001]
- Michael J. Fox Foundation for Parkinson's Research
Extensive research strongly suggests that amyloid beta (A beta) aggregates in the brain have a central role in Alzheimer's disease (AD) pathogenesis. Pathological A beta deposition is likely due to an altered balance between overproduction and elimination. Rodent studies have suggested that the liver has a major role in A beta degradation. It is possible alterations of liver function could affect brain A beta levels through changes in blood A beta concentration. In this study, we hypothesized hepatic A beta degradation to be impaired in AD subjects. To test our hypothesis, an A beta degradation assay was developed using synthetic fluorescein-labeled A beta 40 and A beta 42 spiked into human liver homogenates. A beta degradation rates were lower in AD-derived homogenates as compared with those from non-demented (ND) control subjects, even after accounting for such covariates as age, sex, and APOE genotype. The protein expression of potential A beta-degrading enzymes were also examined. Neprilysin levels were not different in AD liver samples, while cathepsin D and insulin-degrading enzyme were significantly altered in AD subjects. The results support the possibility that impaired hepatic A beta degradation could be a factor contributing to increased brain A beta accumulation and AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据